CLARITYA Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis

This study is focused on assessing how safe and effective the medicine brepocitinib is for adults with a specific eye condition called non-infectious uveitis, which affects the middle or back part of the eye. Uveitis can cause inflammation, leading to vision problems, and current treatment options may not be sufficient or suitable for everyone. By exploring brepocitinib, the study aims to find a better treatment option for those suffering from this condition, potentially improving their quality of life and addressing a significant unmet medical need. Participants in this study will receive brepocitinib orally, meaning they will take it by mouth. The trial involves comparing the effects of brepocitinib against a placebo, which is a substance with no active drug, to evaluate its effectiveness and safety. The researchers will closely monitor how the participants respond to the treatment to determine its impact on their uveitis symptoms. Although the primary outcomes are not listed, the overall goal is to see if brepocitinib can effectively reduce inflammation and improve vision without causing significant side effects.